Table 14.3.1.1
Overall Summary of Treatment-Emergent Adverse Events (TEAEs)
Safety Analysis Set

	ACI-24 1000ug (N=14)		Placebo (N=7)		Overall (N=21)	
	No. of Patients (%)	No. of Events	No. of Patients (%)	No. of Events	No. of Patients (%)	No. of Events
Any AE	14 (100.0)	147	7 (100.0)	47	21 (100.0)	194
Any Treatment-Related AE	4 (28.6)	16	1 (14.3)	3	5 (23.8)	19
Any Severe AE	1 (7.1)	1	0	0	1 (4.8)	1
Any Severe Treatment-Related AE	0	0	0	0	0	0
Any Serious AE	3 (21.4)	3	2 (28.6)	4	5 (23.8)	7
Any Serious Treatment-Related AE	0	0	0	0	0	0
Any Treatment-Related AE Leading to Study Medication Discontinuation	0	0	0	0	0	0
Any Treatment-Related AE Leading to Early Termination	0	0	0	0	0	0
Any AE Leading to Study Medication Discontinuation	1 (7.1)	1	1 (14.3)	3	2 (9.5)	4
Any AE Leading to Early Termination	1 (7.1)	1	1 (14.3)	1	2 (9.5)	2
Any AE Leading to Death	0	0	0	0	0	0